Oncolys BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Oncolys BioPharma şirketinin toplam hissedar öz sermayesi ¥2.0B ve toplam borcu ¥311.1M olup, bu da borç-öz sermaye oranını 15.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥2.4B ve ¥434.6M dir.

Anahtar bilgiler

15.9%

Borç/özkaynak oranı

JP¥311.10m

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥1.64b
Eşitlik	JP¥1.96b
Toplam yükümlülükler	JP¥434.56m
Toplam varlıklar	JP¥2.40b

Son finansal sağlık güncellemeleri

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Jun 17

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Feb 29

Recent updates

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Jun 17

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Feb 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4588 'nin kısa vadeli varlıkları ( ¥2.3B ) kısa vadeli yükümlülüklerini ( ¥235.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4588 şirketinin kısa vadeli varlıkları ( ¥2.3B ) uzun vadeli yükümlülüklerini ( ¥199.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4588 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4588 şirketinin borç/öz sermaye oranı son 5 yılda 14.6% seviyesinden 15.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4588 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 4588 un, serbest nakit akışı her yıl % 15.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Oncolys BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

Oncolys BioPharma Inc. SHS to Be Deleted from OTC Equity

Recent updates

New major risk - Financial position

Oncolys BioPharma Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: JP¥18.72 loss per share (vs JP¥31.47 loss in 2Q 2023)

Oncolys BioPharma Inc. Announces Complete Enrollment of Phase I Clinical Trial for Telomelysin (OBP-301) - Chemoradiation Combination Therapy

Is Oncolys BioPharma (TSE:4588) A Risky Investment?

New major risk - Financial position

New major risk - Financial position

Health Check: How Prudently Does Oncolys BioPharma (TSE:4588) Use Debt?

New major risk - Financial position

Full year 2023 earnings released: JP¥107 loss per share (vs JP¥66.31 loss in FY 2022)

Oncolys BioPharma Inc., Annual General Meeting, Mar 28, 2024

Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine

Oncolys BioPharma Inc. to Report Q1, 2024 Results on May 10, 2024

New major risk - Financial position

Third quarter 2023 earnings released: JP¥23.01 loss per share (vs JP¥15.28 loss in 3Q 2022)

Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal (GEA) Adenocarcinoma

Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy

Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy

New minor risk - Shareholder dilution

Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin™? in Combination Therapy

Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin™? in Combination Therapy

New minor risk - Revenue size

Second quarter 2023 earnings released: JP¥31.47 loss per share (vs JP¥13.94 loss in 2Q 2022)

Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome

First quarter 2023 earnings released: JP¥18.69 loss per share (vs JP¥18.98 loss in 1Q 2022)

Full year 2022 earnings released: JP¥66.31 loss per share (vs JP¥95.50 loss in FY 2021)

Oncolys BioPharma Inc., Annual General Meeting, Mar 29, 2023

Oncolys BioPharma Inc. to Report Q3, 2023 Results on Nov 10, 2023

No independent directors

Oncolys Biopharma Inc. Provides Financial Forecast for the Fiscal Year Ending December 31, 2022

Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals

Second quarter 2022 earnings released: JP¥13.94 loss per share (vs JP¥17.34 loss in 2Q 2021)

Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022

Oncolys BioPharma Inc. SHS to Be Deleted from OTC Equity

Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: JP¥18.98 loss per share (vs JP¥22.36 loss in 1Q 2021)

No independent directors

Oncolys BioPharma Inc. to Report Q3, 2022 Results on Nov 04, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oncolys Biopharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022

Oncolys BioPharma Inc. Announces Enrollment of First Patient in Phase IIa study for OBP-601

Oncolys BioPharma Inc. Announces First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin in Chemoradiation Combination Therapy for Esophageal Cancer Patients

Second quarter 2021 earnings released: JP¥17.34 loss per share (vs JP¥26.48 loss in 2Q 2020)

Oncolys Biopharma Inc. Announces of the Effect of OBP-2011 Against SARS and MERS

Oncolys Biopharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021

Oncolys BioPharma Inc. Announces That the First Patient Has Been Enrolled in the Investigator- Initiated Phase II Clinical Trial for Telomelysin (OBP-301) -Pembrolizumab and Stereotactic Radiation Combination Therapy for Head and Neck Cancer Patients

Full year 2020 earnings released: JP¥146 loss per share (vs JP¥65.56 loss in FY 2019)

New 90-day low: JP¥1,385

Oncolys BioPharma Inc. announced that it has received ¥42.9024 million in funding from SMBC Nikko Securities Inc., Investment Arm

New 90-day low: JP¥1,525

Oncolys BioPharma Enters into Business Alliance Agreement with Asahi Intecc Co., Ltd

Oncolys BioPharma Inc. Announces Receipt of Upfront Payment in Accordance with License Agreement for OBP-601 (Censavudine)

Oncolys BioPharma Inc. to Report First Half, 2021 Results on Aug 06, 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin